Healthcare provider profile · identity verified

Daniel S. Moore, M.D.

Internal Medicine · DETROIT, MI · NPI 1346265196

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	744	264
Amlodipine Besylate	Amlodipine Besylate	507	181
Losartan Potassium	Losartan Potassium	328	111
Metformin Hcl	Metformin Hcl	289	90
Lisinopril	Lisinopril	213	82
Metoprolol Succinate	Metoprolol Succinate	182	64
Omeprazole	Omeprazole	178	66
Jardiance	Empagliflozin	169	52
Fluticasone Propionate	Fluticasone Propionate	165	58
Eliquis	Apixaban	158	52
Albuterol Sulfate Hfa	Albuterol Sulfate	155	45
Nifedipine Er	Nifedipine	155	50
Gabapentin	Gabapentin	141	56
Tamsulosin Hcl	Tamsulosin Hcl	130	44
Ozempic	Semaglutide	119	25
Pantoprazole Sodium	Pantoprazole Sodium	117	52
Rosuvastatin Calcium	Rosuvastatin Calcium	107	33
Ventolin Hfa	Albuterol Sulfate	103	31
Chlorthalidone	Chlorthalidone	101	36
Hydrochlorothiazide	Hydrochlorothiazide	99	37
Spironolactone	Spironolactone	99	34
Levothyroxine Sodium	Levothyroxine Sodium	98	36
Carvedilol	Carvedilol	90	37
Simvastatin	Simvastatin	83	31
Furosemide	Furosemide	81	34
Diclofenac Sodium	Diclofenac Sodium	80	26
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	79	20
Abrysvo	Rsv Vacc, Pref A And Pref B/Pf	77	77
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	75	34
Famotidine	Famotidine	74	28
Trulicity	Dulaglutide	74	18
Rybelsus	Semaglutide	72	19
Potassium Chloride	Potassium Chloride	58	23
Pravastatin Sodium	Pravastatin Sodium	58	17
Tizanidine Hcl	Tizanidine Hcl	58	13
Methocarbamol	Methocarbamol	57	34
Pregabalin	Pregabalin	56	16
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	51	12
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	50	17
Alendronate Sodium	Alendronate Sodium	49	20
Acetaminophen-Codeine	Acetaminophen With Codeine	47	13
Metoprolol Tartrate	Metoprolol Tartrate	47	13
Allopurinol	Allopurinol	46	14
Metformin Hcl Er	Metformin Hcl	46	17
Duloxetine Hcl	Duloxetine Hcl	43	16
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	39	24
Ibuprofen	Ibuprofen	39	17
Ammonium Lactate	Ammonium Lactate	38	12
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	33	suppressed
Hydralazine Hcl	Hydralazine Hcl	29	suppressed
Sertraline Hcl	Sertraline Hcl	29	suppressed
Mounjaro	Tirzepatide	28	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	27	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	27	suppressed
Montelukast Sodium	Montelukast Sodium	27	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	27	suppressed
Shingrix	Varicella-Zoster Ge/As01b/Pf	26	23
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	26	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	25	11
Tramadol Hcl	Tramadol Hcl	25	suppressed
Eplerenone	Eplerenone	23	suppressed
Felodipine Er	Felodipine	23	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	23	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	23	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	22	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	21	16
Xarelto	Rivaroxaban	21	suppressed
Colchicine	Colchicine	20	suppressed
Januvia	Sitagliptin Phosphate	20	suppressed
Labetalol Hcl	Labetalol Hcl	20	suppressed
Nystatin	Nystatin	20	suppressed
Trazodone Hcl	Trazodone Hcl	20	suppressed
Valacyclovir	Valacyclovir Hcl	20	suppressed
Baclofen	Baclofen	19	suppressed
Bevespi Aerosphere	Glycopyrrolate/Formoterol Fum	19	suppressed
Clotrimazole	Clotrimazole	19	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	19	suppressed
Glipizide	Glipizide	18	suppressed
Ipratropium Bromide	Ipratropium Bromide	18	suppressed
Levetiracetam	Levetiracetam	18	suppressed
Naproxen	Naproxen	18	suppressed
Amlodipine-Olmesartan	Amlodipine Bes/Olmesartan Med	17	suppressed
Breo Ellipta	Fluticasone/Vilanterol	17	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	17	suppressed
Spiriva Respimat	Tiotropium Bromide	17	suppressed
Azelastine Hcl	Azelastine Hcl	16	suppressed
Bupropion Hcl Sr	Bupropion Hcl	16	suppressed
Farxiga	Dapagliflozin Propanediol	16	suppressed
Finasteride	Finasteride	16	suppressed
Hydrocortisone	Hydrocortisone	16	11
Oxycodone Hcl	Oxycodone Hcl	16	suppressed
Tenivac	Tetanus-Diphtheria Toxoids/Pf	16	16
Topiramate	Topiramate	16	suppressed
Ultra-Fine Nano Pen Needle	Pen Needle, Diabetic	16	suppressed
Warfarin Sodium	Warfarin Sodium	16	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	16	suppressed
Alprazolam	Alprazolam	15	suppressed
Citalopram Hbr	Citalopram Hydrobromide	14	suppressed
Incruse Ellipta	Umeclidinium Bromide	14	suppressed
Memantine Hcl	Memantine Hcl	14	suppressed
Alcohol Prep Pads	Alcohol Antiseptic Pads	13	suppressed
Buprenorphine	Buprenorphine	13	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	13	suppressed
Ketoconazole	Ketoconazole	13	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	13	suppressed
Vitamin D2	Ergocalciferol (Vitamin D2)	13	suppressed
Atenolol	Atenolol	12	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	12	suppressed
Donepezil Hcl	Donepezil Hcl	12	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	12	suppressed
Propranolol Hcl Er	Propranolol Hcl	12	suppressed
Stiolto Respimat	Tiotropium Br/Olodaterol Hcl	12	suppressed
Terazosin Hcl	Terazosin Hcl	12	suppressed
Verapamil Er	Verapamil Hcl	12	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	11	suppressed
Prednisone	Prednisone	11	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error